Intrapleural Ropivacaine Infusion in Cardiac Surgery

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

September 25, 2025

Primary Completion Date

September 25, 2027

Study Completion Date

December 1, 2027

Conditions
Cardiac SurgeryCoronary Artery DiseaseValvular Diseases
Interventions
DRUG

Ropivacaine

The patient will receive 0.2% ropivacaine (20.0 ml) into the pleural cavity intraoperatively before sternal closure. A continuous infusion of 0.2% ropivacaine will be administered through a microcatheter into the drained pleural cavity, with titration of the infusion rate. The initial infusion rate is set at 10 ml/hour.

DRUG

0.9 % NaCl

The patient will receive 20.0 ml of a 0.9% sodium chloride solution into the pleural cavity intraoperatively, prior to sternal closure. A continuous infusion of 0.9% sodium chloride solution will then be administered through a microcatheter into the drained pleural cavity. The initial infusion rate is set at 10 ml/hour.

All Listed Sponsors
lead

Saint Petersburg State University, Russia

OTHER

NCT07116343 - Intrapleural Ropivacaine Infusion in Cardiac Surgery | Biotech Hunter | Biotech Hunter